• Home
  • » 
  • Reports
  • » 
  • Vaccine Contract Manufacturing Market, 2016 - 2026

Vaccine Contract Manufacturing Market, 2016 - 2026

  • Lowest Price Guaranteed From USD 2,349

  • Published
    June 2016

  • Pages
    265

  • View Count
    4275

  • Buy Now

Example Insights

An updated edition is available at the following link 

View 2nd edition

  1. Vaccine development and manufacturing, characterized by complex production processes and high entry barriers, is set in a highly regulated market landscape. Outsourcing has emerged as a rising trend in this domain and gained a lot of traction in the last few years. As the market continues to evolve, CMOs are rapidly enhancing their service offering to offer end-to-end services to their clients.
  2. Developed regions, such as North America and Europe, currently dominate the vaccine contract manufacturing market. Of the 79 CMOs we identified, 41 have presence in multiple locations in the US. In Europe, the other major hub for CMOs, 20 CMOs have facilities located in Germany, France and the UK alone.
  3. CMOs in emerging locations have also gained ground. With increasing support from local governments, many low-income geographies have restructured their indigenous regulatory landscape. Intellectual property protection laws have been made more stringent in favor of foreign sponsors looking to outsource business operations in the same regions.  Established players in this market have also received the necessary qualifications and certifications to provide services in compliance with global standards.
  4. Out of 79 CMOs, 21 offer end-to-end services across preclinical, clinical and commercial scale. We observed a rapid adoption of mammalian and insect production technologies among service providers.
  5. The highly competitive market landscape is abuzz with partnership activity. We have identified 128 unique partnerships that were inked in the recent past. Of these, a sizeable proportion (25%) is mergers / acquisitions. We believe this trend is likely to continue in the future.
  6. Technological advances are amongst the major driving factors in this market. The introduction of novel expression systems, such as the EB66® and GPEx® cell lines, and cell culture media platforms have sustained the interest of players in this field. Single use / disposable technologies, a key bio-manufacturing trend, are also becoming more and more popular among contract manufacturers. This is representative of the current market intensity.
  7. Driven by increasing global demand and the rapidly expanding vaccine market, we expect the overall contract manufacturing market in this space to grow at an annualized rate of 9.8%. The rate of growth is likely to vary significantly across different segments / activities and across geographical regions.

Report Description

Vaccines have always been viewed as a low-margin business characterized by high entry barriers. Developmental and production related complexities, combined with significant fixed costs and stringent regulatory standards,have limited competition among vaccine manufacturers. In addition, these complexities have also restricted innovation in this space to a great extent. However, recent advances in biotechnology and biomanufacturing have resulted in the development of advanced technologies capable of addressing the challenges associated with manufacturing vaccines. Previously, the vaccine market was solely focused on preventive vaccines developed against infectious diseases. The advent of therapeutic vaccines has renewed interest in this field by paving way for vaccines to be developed for a variety of chronic and degenerative diseases. This has led to the entry of a number of established and emerging stakeholders who are competing for a share in this growing market segment.

It is well-known that the overall trend of outsourcing has grown significantly in the biopharmaceuticals industry. Due to the complex nature of vaccine development and manufacturing processes, both large and small stakeholders are exploring outsourcing opportunities for their products. Operational and infrastructural cost-benefits and reduced time-to-market are the major factors driving outsourcing. Manufacturing vaccines requires specialized resources and highly regulated technology platforms, which are becoming increasingly difficult to establish in-house. Although big pharma players prefer to carry out most of these processes in-house, they are gradually entering into long-term partnerships with trusted contract manufacturing organizations (CMOs). On the other hand, smaller and emerging players have been known to outsource a relatively larger share of their clinical development and commercial manufacturing processes to contract manufacturing partners. The landscape is rapidly evolving. CMOs aiming to consolidate their presence in the market are expanding their service portfolios to provide end-to-end services to their clients and sponsors.

 

Scope of the Report

The "Vaccine Contract Manufacturing Market, 2016 – 2026" report provides an extensive study of the current market landscape of CMOs focused on vaccines. The study presents an in-depth analysis of a diverse set of biopharmaceutical CMOs based on key parameters such as geographical location, scale of operation, use of expression systems and manufacturing capabilities. In addition, it captures some of the potential growth areas that will likely present tremendous opportunities for vaccine CMOs and contribute to an accelerated pace of growth.

The report assesses the key drivers that have governed the evolution of vaccine contract manufacturing market over the past several years, along with an elaborate discussion on the future trends that are likely to shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity for vaccine CMOs market over the next decade, segmented on the basis of business operations, type of expression systems and key regions. 

The study also provides information on some of the most important aspects of vaccine outsourcing; these include growing collaborations, investment activity, facility expansions and technological advances. In addition to some of the well-known benefits and a promising outlook, the study highlights considerable challenges that are currently prevalent in the market. Examples include quality concerns, stringent regulations and lack of funding. Nevertheless, these challenges are resulting in new strategies and technological improvements, which are likely to prove advantageous in the long run.

The base year for the report is 2016; it provides market forecasts for the period 2016 - 2026. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Contents

Chapter 2  provides an executive summary of the key insights captured in our research. The summary offers a high level view on the current status of the vaccine contract manufacturing market and where it is headed in the mid-long term.

Chapter 3  is a general introduction to vaccines. The chapter also includes an overview of the various expression systems used in the development of different vaccines and their related manufacturing procedures. It also provides an elaborate discussion on the need for outsourcing vaccine development and manufacturing processes. In this chapter, we have also presented a list of commonly outsourced biomanufacturing activities that we came across during the course of our research. The chapter also features a section dedicated to the challenges associated with the market.

Chapter 4  provides a comprehensive overview of the global landscape of vaccine CMOs. The chapter includes in-depth analysis based on regional distribution, scale of operation, manufacturing capabilities, type of vaccines manufactured and expression systems used.

Chapter 5  features an analysis of the trends, regulatory landscape and highlights the key players in vaccine contract manufacturing located in the US and Europe, the two leading geographies in this market. The chapter also provides a sub-market forecast for vaccine contract manufacturing segmented on the basis of expression systems used. 

Chapter 6  provides details of vaccine contract manufacturing activities in China and India. It includes information on the regulatory framework, growth drivers and challenges associated with vaccine contract manufacturing in these regions. It also provides a high-level view on the production capabilities of some the key players in these emerging geographies. Additionally, a sub-market forecast for vaccine contract manufacturing segmented on the basis of expression systems used is also included in this chapter.

Chapter 7  presents an analysis of the recent developments in the vaccine contract manufacturing market. It provides a listing of the partnerships established in the recent past, along with an overview of other observed market trends, including investments and facility expansions.

Chapter 8  presents a detailed market forecast for the vaccine contract manufacturing market. Additionally, we have analyzed the future potential for specific geographies across the globe and in terms of the type of expression systems used. To account for the uncertain nature of the market, we have presented three different tracks of market evolution, namely the conservative, base and optimistic scenarios.

Chapter 9  provides a SWOT analysis capturing the key elements that are likely to influence the market’s future.

Chapter 10  highlights future trends that are likely to emerge in the evolving vaccine contract manufacturing market. It includes brief discussions on important aspects such as the adoption of innovative technologies and a shift to strategic partnering. The chapter also addresses the growing market demand and how it is likely to influence the future growth and evolution of this market.

Chapter 11  is a summary of the entire report. It providesthe key takeaways and presents our independent opinion of the vaccine CMOs market, based on the research and analysis described in the previous chapters.

Chapter 12  contains the transcripts of interviews conducted with representatives from renowned organizations engaged in this space.

Chapter 13  is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14  is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1.Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Classification of Vaccines: Based on Type Active Ingredient
3.2.1. Live, Attenuated Vaccines
3.2.2. Inactivated Vaccines
3.2.3. Subunit Vaccines
3.2.4. Toxoid Vaccines
3.2.5. DNA Vaccines
 
3.3. Vaccine Formulations: Key Components
3.3.1. Adjuvants
3.4. Vaccine Development and Manufacturing
3.4.1. Identification of the Antigen and Manufacturing Process Development
3.4.2. Manufacturing Process
3.4.2.1. Upstream Process
3.4.2.1.1. Bacterial Expression Systems
3.4.2.1.2. Yeast Expression Systems
3.4.2.1.3. Insect Expression System
3.4.2.1.4. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.4.2.1.5. Mammalian Expression Systems
3.4.2.1.6. Plant Expression Systems
3.4.2.1.7. Avian Expression Systems
3.4.2.2. Downstream Process
3.4.2.3. Formulation and Fill/Finish
3.4.3. Clinical Development and Approval
 
3.5. Contract Manufacturing: Definition
3.5.1. Vaccine Contract Manufacturing: Addressing an Unmet Need
3.5.2. Vaccine Contract Manufacturing: Commonly Outsourced Operations
3.5.3. Vaccine Contract Manufacturing: Selecting a CMO Partner
3.5.4. Vaccine Contract Manufacturing: Risk Factors and Challenges
 
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Analysis by Region
4.3. Analysis by Scale of Operation
4.4. Analysis by Expression Systems
4.5. Analysis by Manufacturing Capabilities
 
5. VACCINE CONTRACT MANUFACTURING: DEVELOPED REGIONS
5.1. Chapter Overview
5.2. One Stop Shops: A Growing Trend in Vaccine Contract Manufacturing
5.3. Vaccine Outsourcing in the US
5.4. Vaccine Contract Manufacturing Market in the US, 2016 - 2026
5.5. Vaccine Contract Manufacturing Market in the US, 2016 – 2026: Distribution by Type of Expression Systems Used
 
5.6. Leading Vaccine CMOs in the US
5.6.1. Albany Molecular Research (AMRI) / OSO Biopharmaceuticals Manufacturing (OsoBio)
5.6.1.1. Company Overview
5.6.1.2. Vaccine-related Service Portfolio
5.6.1.2.1. Regulatory Support and Quality Assurance
5.6.1.2.2. Vaccine Manufacturing Infrastructure
5.6.1.3. Financial Performance
5.6.1.4. Recent Developments
5.6.1.4.1. Partnerships
5.6.1.4.2. Awards and Recognition
5.6.1.4.3. Expansions
 
5.6.2. Catalent
5.6.2.1. Company Overview
5.6.2.2. Vaccine-related Service Portfolio
5.6.2.2.1. Cell Line Development
5.6.2.2.2. Clinical Manufacturing
5.6.2.2.3. Analytical, Clinical Supply Services
5.6.2.2.4. Regulatory Services
5.6.2.2.5. Vaccine Manufacturing Facilities
5.6.2.2.5.1. Swindon, United Kingdom
5.6.2.2.5.2. Neder-Over-Heembeek, Belgium
5.6.2.2.5.3. Kansas City, Missouri
5.6.2.3. Financial Performance
5.6.2.4. Recent Developments
5.6.2.4.1. Partnerships
5.6.2.4.2. Funding Instances and Expansions
 
5.6.3. Charles River Laboratories
5.6.3.1. Company Overview
5.6.3.2. Vaccine-related Service Portfolio
5.6.3.2.1. Vaccine Development Services
5.6.3.2.2. Vaccine Manufacturing Services
5.6.3.2.3. Avian Vaccine Services
5.6.3.3. Financial Performance
5.6.3.4. Recent Developments
5.6.3.4.1. Partnerships
5.6.3.4.2. Awards and Recognition
5.6.3.4.3. Expansions
 
5.6.4. Lonza
5.6.4.1. Company Overview
5.6.4.2. Vaccine-related Service Portfolio
5.6.4.2.1. Process Development and Optimization
5.6.4.2.2. Commercial Manufacturing
5.6.4.2.3. Aseptic Fill/Finish
5.6.4.2.4. Other Services
5.6.4.3. Financial Performance
5.6.4.4. Recent Developments
5.6.4.4.1. Partnerships
5.6.4.4.2. Expansions
 
5.6.5. Meridian Life Science (MLS)
5.6.5.1. Company Overview
5.6.5.2. Vaccine-related Service Portfolio
5.6.5.2.1. Vaccine Manufacturing Facility at Memphis, Tennessee
5.6.5.2.1.1. Cell and Virus Banking
5.6.5.2.1.2. Process development and Scale-up Services
5.6.5.2.1.3. Formulation Development and Fill/finish
5.6.5.2.1.4. Regulatory Support
5.6.5.2.1.5. Other Services and Facilities
5.6.5.3. Financial Performance
5.6.5.4. Recent Developments
5.6.5.4.1. Partnerships
5.6.5.4.2. Awards and Recognition
5.6.5.4.3. Expansions
 
5.6.6. SAFC (A Unit of Sigma-Aldrich Corporation)
5.6.6.1. Company Overview
5.6.6.2. Vaccine-related Manufacturing Services
5.6.6.2.1. cGMP Cell and Virus Banking
5.6.6.2.2. Process Development
5.6.6.2.3. Biorepository Services
5.6.6.2.4. Contract Manufacturing Support Services
5.6.6.2.5. Vaccine Manufacturing Capabilities
5.6.6.2.5.1. Carlsbad Facility
5.6.6.3. Financial Performance
5.6.6.4. Recent Developments
5.6.6.4.1. Partnerships
5.6.6.4.2. Awards and Recognition
5.6.6.4.3. Expansions
 
5.7. Vaccine Outsourcing in Europe
5.8. Vaccine Contract Manufacturing Market in Europe, 2016 - 2026
5.9. Vaccine Contract Manufacturing Market in Europe, 2016 – 2026: Distribution by Type of Expression Systems Used
 
5.10. Leading Vaccine CMOs in Europe
5.10.1. Cobra Biologics
5.10.1.1. Company Overview
5.10.1.2. Vaccine-related Service Portfolio
5.10.1.2.1. DNA Vaccines and DNA based Services
5.10.1.2.2. Viral Vaccines and Virus based Services
5.10.1.2.3. Other Services
5.10.1.3. Recent Developments
5.10.1.3.1. Partnerships
5.10.1.3.2. Funding Instances and Expansions
 
5.10.2. Eurogentec
5.10.2.1. Company Overview
5.10.2.2. Vaccine-related Service Portfolio
5.10.2.2.1. Manufacturing Services
5.10.2.2.2. Analytical and Regulatory Support
5.10.2.2.3. Other Services
5.10.2.3. Recent Developments
5.10.2.3.1. Partnerships
 
5.10.3. IDT Biologika
5.10.3.1. Company Overview
5.10.3.2. Vaccine-related Service Portfolio
5.10.3.2.1. Development Services
5.10.3.2.2. Manufacturing Services
5.10.3.2.3. Fill/Finish Operations
5.10.3.2.4. Supporting Services
5.10.3.2.4.1. Labeling and Packaging
5.10.3.2.4.2. Storage
5.10.3.2.4.3. Quality Control
5.10.3.2.5. Vaccine Manufacturing Facilities
5.10.3.2.5.1. Riems, Germany
5.10.3.2.5.2. Dessau, Germany
5.10.3.2.5.3. Rockville, Maryland
5.10.3.3. Financial Performance
5.10.3.4. Recent Developments
5.10.3.4.1. Partnerships
5.10.3.4.2. Awards and Recognition
5.10.3.4.3. Expansions
 
5.10.4. SynCo Bio Partners
5.10.4.1. Company Overview
5.10.4.2. Vaccine-related Service Portfolio
5.10.4.2.1. Process Development
5.10.4.2.1.1. Microbial Process Development
5.10.4.2.1.2. Product Development for Live Biotherapeutics
5.10.4.2.2. Analytical and Quality Control Services
5.10.4.2.3. GMP Manufacturing
5.10.4.2.4. Aseptic Filling and Lyophilization Services
5.10.4.2.5. Quality Assurance and Regulatory Support
5.10.4.3. Recent Developments
5.10.4.3.1. Partnerships
5.10.4.3.2. Awards and Recognition
5.10.4.3.3. Expansions
 
6. VACCINE CONTRACT MANUFACTURING: EMERGING REGIONS
6.1. Chapter Overview
6.2. Vaccine Contract Manufacturing in China
6.2.1. Contract Manufacturing in China: Regulatory Landscape
6.2.2. Contract Manufacturing in China: Key Challenges
6.2.3. Vaccine Contract Manufacturing in China: Investments and Business Expansions
6.3. Vaccine Contract Manufacturing Market in China, 2016 - 2026
6.4. Vaccine Contract Manufacturing Market in China, 2016 – 2026: Distribution by Type of Expression Systems Used
 
6.5. Leading Vaccine CMOs in China
6.5.1. GreenPak Biotech
6.5.1.1. Company Overview
6.5.1.2. Vaccine-related Service Portfolio
 
6.5.2. Hong Kong Institute of Biotechnology
6.5.2.1. Company Overview
6.5.2.2. Vaccine-related Service Portfolio
6.5.2.2.1. The Biologics Unit at the Hong Kong Institute of Biotechnology
6.5.2.2.2. Vaccine Contract Manufacturing
 
6.5.3. WuXi AppTec
6.5.3.1. Company Overview
6.5.3.2. Vaccine-related Service Portfolio
6.5.3.2.1. Discovery and Early Diagnostic Testing Services
6.5.3.2.2. Non-Clinical Services
6.5.3.2.3. Support Services
6.5.3.2.4. Manufacturing Services
6.5.3.2.5. Vaccine Testing
6.5.3.3. Financial Performance
6.5.3.4. Recent Developments
6.5.3.4.1. Collaborations and Mergers
 
6.6. Vaccine Contract Manufacturing in India
6.6.1. Contract Manufacturing in India: Regulatory Landscape
6.6.2. Contract Manufacturing in India: Key Challenges
6.7. Vaccine Contract Manufacturing Market in India, 2016 - 2026
6.8. Vaccine Contract Manufacturing Market in India, 2016 – 2026: Distribution by Type of Expression Systems Used
 
6.9. Leading Vaccine CMOs in India
6.9.1. Bharat Biotech
6.9.1.1. Company Overview
6.9.1.2. Vaccine-related Service Portfolio
6.9.1.3. Financial Performance
6.9.1.4. Recent Developments
6.9.1.4.1. Partnerships
6.9.1.4.2. Awards and Fundings
 
6.9.2. Biological E
6.9.2.1. Company Overview
6.9.2.2. Vaccine-related Service Portfolio
6.9.2.2.1. Complete Service Portfolio
6.9.2.3. Financial Performance
6.9.2.4. Recent Developments
6.9.2.4.1. Partnerships
6.9.2.4.2. Awards and Recognition
6.9.2.4.3. Expansions
 
7. RECENT DEVELOPMENTS
7.1. Chapter Overview
7.2. Vaccine Contract Manufacturing Market: Partnerships
7.2.1. Vaccine Contract Manufacturing Market: Growing Trend of Partnerships
7.2.2. Vaccine Contract Manufacturing Market: Analysis by Type of Partnership
7.2.3. Vaccine Contract Manufacturing Market: Analysis by Relevance of Partnership
7.3. Vaccine Contract Manufacturing Market: Capability Expansions
 
8. MARKET FORECAST
8.1. Chapter Overview
8.2. Forecast Methodology
8.3. Vaccine Contract Manufacturing Market. 2016 - 2026
8.4. Vaccine Contract Manufacturing Market: Regional Distribution
8.5. Vaccine Contract Manufacturing Market: Distribution by Type of Expression Systems Used
 
9. SWOT ANALYSIS
9.1. Chapter Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats
 
10. FUTURE TRENDS
10.1. Chapter Overview
10.2. Innovative Technologies to Drive Growth
10.3. The Advent of VLPs
10.4. Cell Culture Media Optimization
10.5. Growing Demand likely to Spur Additional Investments
10.6. Shift toward Strategic Partnering
10.7. Acquisition of Smaller Businesses
 
11. CONCLUSION
 
12. INTERVIEW TRANSCRIPTS
 
13. APPENDIX I TABULATED DATA
 
14. APPENDIX II LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Vaccine Manufacturing: Common Processes
Figure 3.2 Types of Third Party Service Providers in the Pharmaceutical Industry
Figure 3.3 Commonly Outsourced Vaccine Development Operations
Figure 4.1 Vaccine CMOs: Geographical Presence by Country
Figure 4.2 Vaccine CMOs: Geographical Presence by Region
Figure 4.3 Vaccine CMOs: Distribution by Scale of Operation
Figure 4.4 Vaccine CMOs: Distribution by Expression Systems
Figure 4.5 Vaccine CMOs: Availability of Manufacturing Capabilities
Figure 5.1 Vaccine Contract Manufacturing Market in the US: Growth Drivers and Challenges
Figure 5.2 Vaccine Contract Manufacturing Market in the US, 2016 – 2026: Base Scenario (USD Billion)
Figure 5.3 Vaccine Contract Manufacturing Market in the US, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 5.4 AMRI (OsoBio): Vaccine-related Service Portfolio
Figure 5.5 AMRI (OsoBio): Annual Revenues, FY 2011 – Q1 2016 (USD Million)
Figure 5.6 AMRI (OsoBio): Revenues by Business Segments, FY 2015 (USD Million)
Figure 5.7 Catalent: Vaccine-related Service Portfolio
Figure 5.8 Catalent: Annual Revenues, FY 2011 – FY 2015 (USD Billion)
Figure 5.9 Catalent: Revenues by Business Segments, FY 2015 (USD Billion)
Figure 5.10 Charles River Laboratories: Products and Services
Figure 5.11 Charles River Laboratories: Annual Revenues, FY 2011 – FY 2015 (USD Billion)
Figure 5.12 Charles River Laboratories: Revenues by Business Segments, FY 2015 (USD Billion)
Figure 5.13 Lonza: Vaccine-related Service Portfolio
Figure 5.14 Lonza: Annual Revenues, FY 2011 – FY 2015 (CHF Billion)
Figure 5.15 Lonza: Revenues by Business Segments, 2015 (CHF Billion)
Figure 5.16 MLS: Process Development and Scale-up Services
Figure 5.17 MLS: Annual Revenues, FY 2011 – FY 2015 (USD Million)
Figure 5.18 MLS: Revenues by Business Segments, FY 2015 (USD Million)
Figure 5.19 SAFC: Contract Manufacturing Services and Solutions
Figure 5.20 SAFC: Contract Manufacturing Support Services
Figure 5.21 SAFC Carlsbad Facility: Vaccine Manufacturing Services
Figure 5.22 Sigma-Aldrich: Annual Revenues, FY 2010 – FY 2014 (USD Billion)
Figure 5.23 Sigma-Aldrich: Revenues by Business Segments, FY 2014 (USD Billion)
Figure 5.24 Vaccine Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 5.25 Vaccine Contract Manufacturing Market in Europe, 2016 – 2026: Base Scenario (USD Billion)
Figure 5.26 Vaccine Contract Manufacturing Market in Europe, 2016 - 2026: Distribution byType of Expression Systems Used (USD Billion)
Figure 5.27 Eurogentec: Manufacturing Technologies and Capabilities
Figure 5.28 IDT Biologika: Vaccine-related Service Portfolio
Figure 5.29 IDT Biologika: Annual Revenues, FY 2011 – FY 2015 (EUR Million)
Figure 5.30 SynCo Bio Partners: Vaccine-related Service Portfolio
Figure 6.1 Contract Manufacturing Market in China: Key Growth Drivers
Figure 6.2 Vaccine Contract Manufacturing Market in China, 2016 – 2026: Base Scenario (USD Billion)
Figure 6.3 Vaccine Contract Manufacturing Market in China, 2016 – 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 6.4 Hong Kong Institute of Biotechnology: Service Portfolio
Figure 6.5 WuXi AppTec: Vaccine Development Services
Figure 6.6 WuXi AppTec: Vaccine Testing Services
Figure 6.7 Contract Manufacturing Market in India: Key Drivers and Concerns
Figure 6.8 Vaccine Contract Manufacturing Market in India, 2016 – 2026: Base Scenario (USD Billion)
Figure 6.9 Vaccine Contract Manufacturing Market in India, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 6.10 Biological E: Vaccine-related Service Portfolio
Figure 7.1 Vaccine Contract Manufacturing Market: Cumulative Trend of Partnerships, Pre 2009 - 2016
Figure 7.2 Vaccine Contract Manufacturing Market: Distribution by Type of Partnership
Figure 7.3 Vaccine Contract Manufacturing Market: Distribution by Relevance of Partnership
Figure 8.1 Share of Contract Manufacturers in the Vaccines Market
Figure 8.2 Vaccine Market, 2016 – 2026 (USD Billion)
Figure 8.3 Vaccine Manufacturing Market, 2016 – 2026: Base Scenario (USD Billion)
Figure 8.4 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution (USD Billion)
Figure 8.5 Vaccine Contract Manufacturing Market: Regional Distribution 2016, 2021 and 2026
Figure 8.6 Vaccine Contract Manufacturing Market, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 9.1 Vaccines in the Development Pipeline: By Therapeutic Area

List of Tables

Table 3.1 Vaccines and Small Molecule Drugs: Key Differences
Table 3.2 Vaccines: Classification Based on Method of Development
Table 3.3 Live Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.4 Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.5 Subunit Vaccines: Commonly Reported Adverse Events
Table 3.6 Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.7 Vaccine Excipients and their Functions
Table 4.1 Vaccine CMOs: Geographical Distribution
Table 4.2 Vaccine CMOs: Overview of Scales of Operation
Table 4.3 Vaccine CMOs: Types of Expression Systems Used
Table 4.4 Vaccine CMOs: Manufacturing Capabilities
Table 5.1 Companies Providing One Stop Shop Services
Table 5.2 AMRI (OsoBio): Partnerships
Table 5.3 Catalent: Biologics Manufacturing and Laboratory Facilities
Table 5.4 Catalent: Partnerships
Table 5.5 Charles River Laboratories: Partnerships
Table 5.6 Lonza: Partnerships
Table 5.7 MLS: Partnerships
Table 5.8 SAFC: Partnerships
Table 5.9 Cobra Biologics: Production Facilities
Table 5.10 Cobra Biologics: Partnerships
Table 5.11 Cobra Biologics: Funding Instances
Table 5.12 Eurogentec: Partnerships
Table 5.13 IDT Biologika: Partnerships
Table 5.14 SynCo Bio Partners: Partnerships
Table 6.1 Hong Kong Institute of Biotechnology: Vaccine Contract Manufacturing Services
Table 6.2 WuXi AppTec: Biologics Development and Manufacturing Services
Table 6.3 Bharat Biotech: Partnerships
Table 6.4 Biological E: Partnerships
Table 7.1 Vaccine Contract Manufacturing Market: Partnerships
Table 9.1 Vaccine Contract Manufacturing Market: SWOT Analysis
Table 13.1 Vaccine CMOs: Geographical Presence by Country
Table 13.2 Vaccine CMOs: Geographical Presence by Region
Table 13.3 Vaccine CMOs: Distribution by Scale of Operation
Table 13.4 Vaccine CMOs: Distribution by Expression Systems
Table 13.5 Vaccine CMOs: Availability of Manufacturing Capabilities
Table 13.6 Vaccines Contract Manufacturing Market in the US, 2016 – 2026: Base Scenario (USD Billion)
Table 13.7 Vaccine Contract Manufacturing Market in the US, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Table 13.8 AMRI (OsoBio): Annual Revenues, FY 2011 – Q1 2016 (USD Million)
Table 13.9 AMRI (OsoBio): Revenues by Business Segments, FY 2015 (USD Million)
Table 13.10 Catalent: Annual Revenues, FY 2011 – FY 2015 (USD Billion)
Table 13.11 Catalent: Revenues by Business Segments, FY 2015 (USD Billion)
Table 13.12 Charles River Laboratories: Annual Revenues, FY 2011 – FY 2015 (USD Billion)
Table 13.13 Charles River Laboratories: Revenues by Business Segments, FY 2015 (USD Billion)
Table 13.14 Lonza: Annual Revenues, FY 2011 – FY 2015 (CHF Billion)
Table 13.15 Lonza: Revenues by Business Segments, 2015 (CHF Billion)
Table 13.16 MLS: Annual Revenues, FY 2011 – FY 2015 (USD Million)
Table 13.17 MLS: Revenues by Business Segments, FY 2015 (USD Million)
Table 13.18 Sigma-Aldrich: Annual Revenues, FY 2010 – FY 2014 (USD Billion)
Table 13.19 Sigma-Aldrich: Revenues by Business Segments, FY 2014 (USD Billion)
Table 13.20 Vaccines Contract Manufacturing Market in Europe, 2016 – 2026: Base Scenario (USD Billion)
Table 13.21 Vaccine Contract Manufacturing Market in Europe, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Table 13.22 IDT Biologika: Annual Revenues, FY 2011 – FY 2015 (EUR Million)
Table 13.23 Vaccines Contract Manufacturing Market in China, 2016 – 2026: Base Scenario (USD Billion)
Table 13.24 Vaccine Contract Manufacturing Market in China, 2016 – 2026: Distribution by Type of Expression Systems Used (USD Billion)
Table 13.25 Vaccines Contract Manufacturing Market in India, 2016 – 2026: Base Scenario (USD Billion)
Table 13.26 Vaccine Contract Manufacturing Market in India, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Table 13.27 Vaccine Contract Manufacturing Partnerships: Cumulative Trend, Pre 2009 -2016
Table 13.28 Vaccine Contract Manufacturing Partnerships: Distribution by Type of Partnership
Table 13.29 Vaccine Contract Manufacturing Partnerships: Distribution by Relevance of Partnership
Table 13.30 Vaccine Market, 2016 – 2026 (USD Billion)
Table 13.31 Vaccine Manufacturing Market, 2016 – 2026: Base Scenario (USD Billion)
Table 13.32 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution (USD Billion)
Table 13.33 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution 2016, 2021 and 2026
Table 13.34 Vaccine Contract Manufacturing Market, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)

Listed Companies

The following companies have been mentioned in the report.

  1. 3P Biopharmaceuticals
  2. ABL
  3. Acambis
  4. Accugenix
  5. Actavis
  6. Advanced BioScience Laboratories
  7. Advaxis
  8. Aeras
  9. Air Force Hospital, Guangzhou
  10. AJ Biologics
  11. Albany Molecular Research (AMRI) 
  12. Alexion
  13. Algonomics
  14. Altaris Capital Partner
  15. AmbioPharm
  16. AnaSpec
  17. Aptuit
  18. Association for Assessment and Accreditation of Laboratory Animal Care
  19. Association Sportive du Golf Club Val de l'Indre
  20. Australian Therapeutic Goods Administration
  21. Avid Bioservices
  22. Bachem
  23. Batavia Biosciences
  24. Bavarian Nordic
  25. Baxter BioPharma Solutions
  26. BD Biosciences
  27. Benchmark Vaccines
  28. Bharat Biotech
  29. Bill and Melinda Gates Foundation 
  30. BioCell Corporation 
  31. Biocon
  32. BioConnections
  33. BioConvergence
  34. Biofabri
  35. Bioline Group of Companies
  36. Biological E
  37. BioMARC
  38. Biomay
  39. Biomedical Advanced Research and Development Authority
  40. BioMotiv
  41. Biopharmaceutical Development Program - Frederick National Laboratory for Cancer Research
  42. BioReliance Holdings
  43. BioTechnique
  44. Biotechnology and Biological Sciences Research Council
  45. Biotechnology and Biological Sciences Research Council
  46. Biovest International
  47. Boehringer Ingelheim 
  48. Boehringer Ingelheim BioXcellence™
  49. Bristol-Myers Squibb
  50. Bryllan
  51. CALIXAR
  52. Canadian Animal Health Institute 
  53. Canadian Council on Animal Care
  54. Catalent
  55. Catalent Pharma Solutions 
  56. Celsis International
  57. Centers for Disease Control and Prevention
  58. CEPiA Sanofi (Transgene)
  59. Cetus Corporation
  60. CEVEC Pharmaceuticals
  61. Charles River Laboratories International
  62. Chimera Biotec
  63. China Agricultural University
  64. China National Biotec Group
  65. Chinese Center for Disease Control and Prevention
  66. Cobra Biologics
  67. Cook Pharmica
  68. Council of the Chinese University of Hong Kong
  69. Crucell Sweden
  70. Cytovance Biologics
  71. Daiichi Sankyo
  72. Deltamune
  73. Developing Countries Vaccine Manufacturers Network
  74. Dr. Reddy's Laboratories 
  75. Emergent BioSolutions
  76. Engineering and Physical Sciences Research Council
  77. Eubiologics
  78. Eurogentec
  79. European Medicines Agency 
  80. Federation of Indian Chambers of Commerce and Industry 
  81. Florida Biologix
  82. Friedrich-Loeffler-Institut
  83. FUJIFILM Diosynth Biotechnologies
  84. Gallant Custom Laboratories
  85. Gamma Vaccines
  86. Genentech
  87. GENEWIZ
  88. GlaxoSmithKline
  89. Global Alliance for Vaccines and Immunizations
  90. GNH India
  91. Goodwin Biotechnology
  92. Government of India's Universal Immunisation Programme 
  93. Grand River Aseptic Manufacturing
  94. GreenPak Biotech
  95. Guangxi Veterinary Research Institute
  96. Haffkine Institute
  97. HALIX
  98. Harbin Veterinary Research Institute
  99. Harbin Veterinary Research Institute, China
  100. HK Jockey Club Charities Trust 
  101. HLL Biotech
  102. Hong Kong Institute of Biotechnology
  103. IDT Biologika
  104. Immune Design
  105. Immune Targeting Systems
  106. ImmunoSite Technologies
  107. ImVisioN Therapeutics
  108. Index Ventures
  109. Indian Council of Medical Research
  110. Indian Immunologicals
  111. Infectious Disease Research Institute
  112. Innovation & Technology Commission, HKSAR Government, China
  113. Integrity Bio
  114. Intercell
  115. International Medica Foundation
  116. International Society for Pharmaceutical Engineering
  117. Interros Group
  118. Inviragen
  119. Irvine Pharmaceutical Services 
  120. Jubilant HollisterStier
  121. KABS Pharmaceutical Services
  122. Kaneka Corporation 
  123. KBI Biopharma
  124. LigoCyte Pharmaceuticals
  125. Lonza
  126. Magellan Biosciences
  127. MassBiologics
  128. Medicago
  129. Mefar Ilac (Birgi Mefar Group)
  130. Meridian Life Science
  131. Ministry of Health & Family Welfare, Government of India
  132. Mitsubishi Gas Chemical Company
  133. Mitsubishi Tanabe Pharma Corporation
  134. Moderna Therapeutics
  135. Mymetics Corporation
  136. National Avian Influenza Reference Laboratory
  137. National Heart, Lung and Blood Institute
  138. National Institutes of Allergy and Infectious Diseases
  139. Norwegian Institute of Public Health
  140. Novartis
  141. Novasep
  142. Novavax
  143. NPO Petrovax Pharm
  144. NTC
  145. OctoPlus
  146. Okairos
  147. Oncotest
  148. Organization for Economic Cooperation and Development
  149. OSO Biopharmaceuticals Manufacturing (OsoBio)
  150. Pacific GMP
  151. Panacea Biotec
  152. Paragon Bioservices 
  153. PATH
  154. Pfenex
  155. Pfizer
  156. Pfizer CentreOne
  157. Pharmapak
  158. PharmaSynth
  159. Premas Biotech
  160. Prime European Therapeuticals
  161. ProBioGen
  162. Protagen
  163. PX’Therapeutics
  164. QuiaPEG
  165. RAFAGEN
  166. Recipharm
  167. Richter-Helm
  168. Riemser Pharma 
  169. SAFC
  170. Sanofi
  171. Sanofi Pasteur
  172. Sartorius Stedim Biotech
  173. Serum Institute 
  174. Shandong Zhaoxin Bio-tech Company
  175. Shanghai Laboratory Animal Commission
  176. ShangPharma
  177. Sigma-Aldrich
  178. South China Agricultural University
  179. Statens Serum Institut
  180. Stellar Biotechnologies
  181. Swiss State Secretariat Education, Research and Innovation
  182. SynCo Bio Partners
  183. Technology Strategy Board
  184. Temasek Life Sciences Ventures
  185. The College of Animal Science and Technology, Sichuan Agricultural University, China
  186. Thermo Fisher Scientific
  187. Tianjin CanSino Biotechnology
  188. UK Medicines Control Agency
  189. Unitech Pharma Group
  190. United States Food and Drug Association
  191. Univercells
  192. University of Maryland
  193. University of Oxford
  194. University of Pennsylvania
  195. Upperton 
  196. Vaccibody
  197. Vacsera
  198. Valneva
  199. Vetter Pharma International
  200. VGXI
  201. Vibalogics
  202. Vivalis
  203. Vybion (Recombinant Protein Technologies and Products)
  204. Waisman Biomanufacturing
  205. Walter Reed Army Institute of Research - Pilot Bioproduction Facility
  206. Wellcome Trust 
  207. WIL Research
  208. World Trade Organization
  209. WuXi AppTec 
  210. Zoetis

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.